Clinical Trials for Mesothelioma Patients—A Study of Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Read about a current clinical trial about the early diagnosis of lung cancer and mesothelioma in prior asbestos workers. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At the present time, this study is only being conducted in Canada.

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Purpose
Occupational exposure to asbestos is known increase the risk of developing cancer of the lungs (bronchogenic carcinoma) or of the pleura (mesothelioma). Symptoms are subtle and non-specific, diagnosis is often late and the prognosis consequently is dismal. Currently there is no accepted non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. In the last decade, low-dose computed tomography (LDCT) has been successfully developed and validated for the early diagnosis of lung cancer in high-risk smokers. Malignant mesothelioma might, in an early stage, resemble a benign pleural plaque, which is a common finding after asbestos exposure. We target to develop low-dose CT as a tool to serially image the pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and, as such, identify the presence of mesothelioma early, before symptoms occur.

Requisite Conditions:
Lung Cancer
Mesothelioma

Study Type and Design:
Observational; case control and other
Further study details as provided by University Health Network, Toronto

Estimated Enrollment: 1,000
Study Start Date: March 2005
Estimated Study Completion Date: March 2010

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.